On the other hand, a higher presence of CD3+, CD8+, PD-1+ [9, 25, 26], tumor infiltrating lymphocytes (TILs) [17, 26, 40] and high mutational tumor burden (TMB) [41] are associated with a better survival while PIK3CA mutations [36, 42] have been associated with worse survival in ASCC irrespective of p16 status. Here, CD8A is linked to neoplasm.